A Study of [14C]-LY4065967 in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
16actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-23 | actual | When the study began enrolling |
| Primary completion | 2025-08-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-16 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: LY4065967
- Radiation: [14C]-LY4065967 Oral
- Radiation: [14C]-LY4065967 IV
Primary outcomes
what the primary-completion date above is the date OFPart 1: Percentage of Total Radioactive Dose in Urine and Fecal Excretion
measured Baseline through Study Completion (21 days)
Part 2: Plasma Area Under the Concentration-time Curve from Zero to Infinity (AUC(0-ꝏ)) for LY4065967
measured Baseline through Study Completion (9 Days)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed